Peptide Mapping Explained: Enzyme Digests, Coverage and Artefacts
An intact mass tells a lab that a peptide has the right overall weight. It does not say whether every residue sits where it should, or where a small modification has landed. Peptide mapping answers both questions. The chain is cut with an enzyme at predictable sites, the pieces are separated and weighed, and the observed pieces are compared with the list the correct sequence should produce. For longer chains, and for QC teams comparing many lots of the same material, it is the routine technique that places a difference at a particular segment of the sequence instead of somewhere in the whole molecule.
How peptide mapping works
The workflow has four steps:
- Digest. A protease with known cleavage rules cuts the peptide into shorter fragments.
- Separate. The digest is run on reversed-phase LC so the fragments elute one by one.
- Measure. Each fragment’s mass is recorded, usually by an in-line mass spectrometer.
- Compare. Observed masses are matched against a list calculated in advance from the expected sequence and the enzyme’s rules.
When every predicted fragment is found at its expected mass, each segment it covers is confirmed. When a fragment appears at the wrong mass, the discrepancy is confined to that stretch of the chain.
Choosing the enzyme
The method only works because the enzyme cuts at defined places. A protease that cut at random would produce an uninterpretable mixture. Common choices:
| Enzyme | Typical cleavage rule | Notes |
|---|---|---|
| Trypsin | After lysine (K) or arginine (R), generally not when the next residue is proline | The default; gives fragments of useful length for most sequences |
| Chymotrypsin | After large aromatic residues (F, W, Y) | Useful where trypsin sites are sparse |
| Glu-C | After glutamate (E); also after aspartate (D) in some buffers | Buffer choice changes specificity, so record it |
| Asp-N | Before aspartate (D) | Cuts on the N-terminal side, giving different boundaries |
Because each enzyme draws its boundaries differently, a region poorly covered by one digest is often well covered by a second digest with another enzyme.
A worked example with an invented sequence
Take a made-up 13-residue peptide, AGKLVSRPFEKGT, digested with trypsin:
- A cut after K3 gives AGK.
- R7 is followed by proline, so trypsin normally skips it.
- A cut after K11 gives LVSRPFEK, leaving GT at the C-terminus.
The dipeptide GT is too small to retain or detect reliably, and the short, polar AGK may be lost as well, so a real map of this sequence might confirm eleven of thirteen residues at best and only the central eight at worst. That gap is not a failure of the material. It is a limit of the chosen enzyme, and it should be written on the report.
Sequence coverage: the number that shows what was not seen
Coverage is the percentage of residues accounted for by identified fragments. It is rarely 100%, because the method has built-in blind spots:
- Very short fragments wash straight through the column or give weak signals.
- Long, hydrophobic fragments may elute poorly or not at all.
- Some fragments ionise badly and are hard to detect.
- Stretches with no cleavage sites produce one oversized fragment that behaves unpredictably.
A coverage figure therefore belongs in the result, together with the uncovered region. High coverage with the gap named is strong evidence. A map without a coverage figure leaves the reader unable to tell what went unexamined.
Missed cleavages and other expected surprises
Enzymes do not cut at every eligible site on every molecule. A site beside proline, beside a modified residue, or inside a region that stays partly folded may be skipped, producing a longer fragment that spans two predicted ones.
This is routine. The predicted list used for interpretation should include plausible missed-cleavage products as well as the fully cut fragments, so that a longer fragment is recognised for what it usually is rather than logged as an impurity.
What peptide mapping can locate that intact mass cannot
This is the main reason to run a map. An intact mass that is 16 Da high says an oxygen was added somewhere, most often by oxidation of methionine. A map shows which fragment carries the extra 16 Da, narrowing it to one residue or a small group. The same logic applies to:
- Deamidation of asparagine or glutamine (a shift of just under 1 Da).
- A leftover protecting group from synthesis.
- A residue substitution that changes one fragment’s mass.
- Disulfide pairing, found by digesting without reducing the bonds and seeing which fragments stay joined, as covered in disulfide formation and scrambling.
To go further and pin a change to a single residue within a fragment, the fragment itself can be broken apart in the mass spectrometer, the approach explained in peptide sequencing by mass spectrometry.
Artefacts the digestion itself can create
A tryptic digest usually runs for hours at around 37 °C and a mildly alkaline pH. Those conditions can change the sample:
- Deamidation. Asparagine residues, particularly those followed by glycine, deamidate readily under these conditions, so a map can report a change the method caused.
- Disulfide scrambling. Mildly alkaline conditions encourage disulfides to swap partners. Connectivity work is often done at lower pH with a shorter digestion to limit this.
- Autolysis. The protease cleaves itself, contributing extra peaks; because the enzyme’s sequence is known, those peaks can be identified and set aside.
- Handling oxidation. Methionine can oxidise during preparation, so finding it in a map does not prove it was in the vial.
The standard controls are a blank digest (enzyme and buffer only) and a reference sample digested side by side under identical conditions.
When a map is worth ordering for bulk material
For a short peptide of around fifteen residues, intact mass already constrains composition tightly, and a map adds cost and time for little extra information. That is why it seldom appears on routine certificates. It earns its place as chains get longer: in a chain of 70 or 80 residues, a single substitution can shift the mass by an amount close to routine measurement error, while a map shows it plainly. For a longer, disulfide-bonded example, see the shift from peptide to protein analysis.
For a lab buying the same long peptide in several lots, overlaid maps from each lot also give a detailed fingerprint for lot-to-lot comparison. Keep the limits in mind: a map cannot detect D-for-L substitutions (the fragment masses are identical), it does not measure purity, and it says nothing about the uncovered portion. Alongside an intact mass and an HPLC purity trace, though, it answers the one question neither of those reaches: whether the residues are in the right order.
Bulk Peptides supplies all products for in-vitro research and analytical laboratory work only; they are not intended for human or veterinary use.
